X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ALEMBIC PHARMA with Cipla - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs CIPLA - Comparison Results

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC PHARMA CIPLA ALEMBIC PHARMA/
CIPLA
 
P/E (TTM) x 28.3 44.2 64.0% View Chart
P/BV x 6.5 3.9 167.4% View Chart
Dividend Yield % 0.7 0.3 219.2%  

Financials

 ALEMBIC PHARMA   CIPLA
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-16
CIPLA
Mar-17
ALEMBIC PHARMA/
CIPLA
5-Yr Chart
Click to enlarge
High Rs792622 127.3%   
Low Rs443458 96.7%   
Sales per share (Unadj.) Rs167.0181.9 91.8%  
Earnings per share (Unadj.) Rs38.212.9 296.5%  
Cash flow per share (Unadj.) Rs42.029.3 143.2%  
Dividends per share (Unadj.) Rs4.002.00 200.0%  
Dividend yield (eoy) %0.60.4 175.0%  
Book value per share (Unadj.) Rs84.9155.7 54.5%  
Shares outstanding (eoy) m188.52804.51 23.4%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x3.73.0 124.5%   
Avg P/E ratio x16.242.0 38.5%  
P/CF ratio (eoy) x14.718.4 79.8%  
Price / Book Value ratio x7.33.5 209.6%  
Dividend payout %10.515.5 67.5%   
Avg Mkt Cap Rs m116,383434,516 26.8%   
No. of employees `000NA23.0 0.0%   
Total wages/salary Rs m4,21426,338 16.0%   
Avg. sales/employee Rs ThNM6,349.1-  
Avg. wages/employee Rs ThNM1,143.0-  
Avg. net profit/employee Rs ThNM449.3-  
INCOME DATA
Net Sales Rs m31,487146,302 21.5%  
Other income Rs m552,287 2.4%   
Total revenues Rs m31,542148,589 21.2%   
Gross profit Rs m10,06024,758 40.6%  
Depreciation Rs m72213,229 5.5%   
Interest Rs m371,594 2.3%   
Profit before tax Rs m9,35612,222 76.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m-2-70 2.1%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,1601,798 120.2%   
Profit after tax Rs m7,19410,354 69.5%  
Gross profit margin %31.916.9 188.8%  
Effective tax rate %23.114.7 157.0%   
Net profit margin %22.87.1 322.8%  
BALANCE SHEET DATA
Current assets Rs m15,06687,370 17.2%   
Current liabilities Rs m7,67433,081 23.2%   
Net working cap to sales %23.537.1 63.3%  
Current ratio x2.02.6 74.3%  
Inventory Days Days6787 77.0%  
Debtors Days Days4162 65.2%  
Net fixed assets Rs m8,237111,567 7.4%   
Share capital Rs m3771,609 23.4%   
"Free" reserves Rs m15,416123,645 12.5%   
Net worth Rs m16,005125,254 12.8%   
Long term debt Rs m036,454 0.0%   
Total assets Rs m24,594209,532 11.7%  
Interest coverage x255.28.7 2,944.5%   
Debt to equity ratio x00.3 0.0%  
Sales to assets ratio x1.30.7 183.4%   
Return on assets %29.45.7 515.6%  
Return on equity %44.98.3 543.7%  
Return on capital %58.78.5 690.3%  
Exports to sales %55.734.2 162.9%   
Imports to sales %10.48.3 125.0%   
Exports (fob) Rs m17,55150,050 35.1%   
Imports (cif) Rs m3,28312,203 26.9%   
Fx inflow Rs m17,81151,066 34.9%   
Fx outflow Rs m5,31817,678 30.1%   
Net fx Rs m12,49333,388 37.4%   
CASH FLOW
From Operations Rs m9,30423,824 39.1%  
From Investments Rs m-3,105-13,127 23.7%  
From Financial Activity Rs m-1,959-13,239 14.8%  
Net Cashflow Rs m4,240-2,478 -171.1%  

Share Holding

Indian Promoters % 74.1 16.0 463.1%  
Foreign collaborators % 0.0 20.8 -  
Indian inst/Mut Fund % 2.9 12.2 23.8%  
FIIs % 9.1 23.7 38.4%  
ADR/GDR % 0.0 1.1 -  
Free float % 13.9 26.2 53.1%  
Shareholders   49,328 161,166 30.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC PHARMA With:   ASTRAZENECA PHARMA  DR. DATSONS LABS  ELDER PHARMA  NOVARTIS  PANACEA BIOTECH  

Compare ALEMBIC PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex, Nifty at Record Close Yet Again; IT & Realty Stocks Rally(Closing)

Indian share markets extended rally in the final hour of the trade, hitting fresh record highs while the Bank nifty touched 27,000 level for the first time. At the closing bell.

Related Views on News

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Cipla: Extraordinary Income Boosts Net Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

Proceeds from the sale of the South African animal business bolstered Cipla's net profits for the quarter.

Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

Mar 8, 2017

Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Jan 22, 2018 (Close)

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA - PLETHICO PHARMA COMPARISON

COMPARE ALEMBIC PHARMA WITH

MARKET STATS